Silvio Steiner

Silvio Steiner

Auto-generated profile, based on publicly available information

Silvio Steiner

Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Nature
Verified
Journal Article
Closed access
PDF file
BZBin Zhou
Bin Zhou
TTTran Thi Nhu Thao
Tran Thi Nhu Thao
DHDonata Hoffmann
Donata Hoffmann
ATAdriano Taddeo
Adriano Taddeo
NENadine Ebert
Nadine Ebert
MBMartin Beer
Martin Beer

15 January 2024 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
SSSilvio Steiner
Silvio Steiner
AKAnnika Kratzel
Annika Kratzel
GBGüliz Tuba Barut
Güliz Tuba Barut
RLReto M. Lang
Reto M. Lang
Etori Aguiar MoreiraEtori Aguiar Moreira
Etori Aguiar Moreira
VTVolker Thiel
Volker Thiel

29 March 2021 in PLOS Biology
Verified
Journal Article
Open access
PDF file
PVPhilip V'kovski
Philip V'kovski
MGMitra Gultom
Mitra Gultom
JKJenna Kelly
Jenna Kelly
SSSilvio Steiner
Silvio Steiner
JRJulie Russeil
Julie Russeil
RDRonald Dijkman
Ronald Dijkman
Since its emergence in December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally and become a major public health burden. Despite its close phylogenetic relationship to SARS-CoV, SARS-CoV-2 exhibits increased human-to-human transmission dynamics, likely due to efficient early replication in the upper respiratory epithelium of infected individuals. Since different temperatures encountered in the human upper and lower respiratory tract (33°C and 37°C, respectively) have been shown to affect the replication kinetics of several respiratory viruses, as well as host innate immune response dynamics, we investigated the impact of temperature on SARS-CoV-2 and SARS-CoV infection using the primary human airway epithelial cell culture model. SARS-CoV-2, in contrast to SARS-CoV, replicated to higher titers when infections were performed at 33°C rather than 37°C. Although both viruses were highly sensitive to type I and type III interferon pretreatment, a detailed time-resolved transcriptome analysis revealed temperature-dependent interferon and pro-inflammatory responses induced by SARS-CoV-2 that were inversely proportional to its replication efficiency at 33°C or 37°C. These data provide crucial insight on pivotal virus–host interaction dynamics and are in line with characteristic clinical features of SARS-CoV-2 and SARS-CoV, as well as their respective transmission efficiencies.

7 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGüliz Tuba Barut
Güliz Tuba Barut
NHNico Joel Halwe
Nico Joel Halwe
ATAdriano Taddeo
Adriano Taddeo
JKJenna Kelly
Jenna Kelly
JSJacob Schön
Jacob Schön
VTVolker Thiel
Volker Thiel
Variant of concern (VOC) Omicron-BA.1 has achieved global predominance in early 2022. Therefore, surveillance and comprehensive characterization of Omicron-BA.1 in advanced primary cell culture systems and animal models are urgently needed. Here, we characterize Omicron-BA.1 and recombinant Omicron-BA.1 spike gene mutants in comparison with VOC Delta in well-differentiated primary human nasal and bronchial epithelial cells in vitro, followed by in vivo fitness characterization in hamsters, ferrets and hACE2-expressing mice, and immunized hACE2-mice. We demonstrate a spike-mediated enhancement of early replication of Omicron-BA.1 in nasal epithelial cultures, but limited replication in bronchial epithelial cultures. In hamsters, Delta shows dominance over Omicron-BA.1, and in ferrets Omicron-BA.1 infection is abortive. In hACE2-knock-in mice, Delta and a Delta spike clone also show dominance over Omicron-BA.1 and an Omicron-BA.1 spike clone, respectively. Interestingly, in naïve K18-hACE2 mice, we observe Delta spike-mediated increased replication and pathogenicity and Omicron-BA.1 spike-mediated reduced replication and pathogenicity, suggesting that the spike gene is a major determinant of replication and pathogenicity. Finally, the Omicron-BA.1 spike clone is less well-controlled by mRNA-vaccination in K18-hACE2-mice and becomes more competitive compared to the progenitor and Delta spike clones, suggesting that spike gene-mediated immune evasion is another important factor that led to Omicron-BA.1 dominance.

22 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
URUrszula Radzikowska
Urszula Radzikowska
AEAndrzej Eljaszewicz
Andrzej Eljaszewicz
GTGe Tan
Ge Tan
NSNino Stocker
Nino Stocker
AHAnja Heider
Anja Heider
MSMilena Sokolowska
Milena Sokolowska
Rhinoviruses and allergens, such as house dust mite are major agents responsible for asthma exacerbations. The influence of pre-existing airway inflammation on the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely unknown. We analyse mechanisms of response to viral infection in experimental in vivo rhinovirus infection in healthy controls and patients with asthma, and in in vitro experiments with house dust mite, rhinovirus and SARS-CoV-2 in human primary airway epithelium. Here, we show that rhinovirus infection in patients with asthma leads to an excessive RIG-I inflammasome activation, which diminishes its accessibility for type I/III interferon responses, leading to their early functional impairment, delayed resolution, prolonged viral clearance and unresolved inflammation in vitro and in vivo. Pre-exposure to house dust mite augments this phenomenon by inflammasome priming and auxiliary inhibition of early type I/III interferon responses. Prior infection with rhinovirus followed by SARS-CoV-2 infection augments RIG-I inflammasome activation and epithelial inflammation. Timely inhibition of the epithelial RIG-I inflammasome may lead to more efficient viral clearance and lower the burden of rhinovirus and SARS-CoV-2 infections.

12 July 2024 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
JSJacob Schön
Jacob Schön
GBGüliz Tuba Barut
Güliz Tuba Barut
BTBettina Salome Trüeb
Bettina Salome Trüeb
NHNico Joel Halwe
Nico Joel Halwe
IVInês Berenguer Veiga
Inês Berenguer Veiga
VTVolker Thiel
Volker Thiel
Approved vaccines are effective against severe COVID-19, but broader immunity is needed against new variants and transmission. Therefore, we developed genome-modified live-attenuated vaccines (LAV) by recoding the SARS-CoV-2 genome, including ‘one-to-stop’ (OTS) codons, disabling Nsp1 translational repression and removing ORF6, 7ab and 8 to boost host immune responses, as well as the spike polybasic cleavage site to optimize the safety profile. The resulting OTS-modified SARS-CoV-2 LAVs, designated as OTS-206 and OTS-228, are genetically stable and can be intranasally administered, while being adjustable and sustainable regarding the level of attenuation. OTS-228 exhibits an optimal safety profile in preclinical animal models, with no side effects or detectable transmission. A single-dose vaccination induces a sterilizing immunity in vivo against homologous WT SARS-CoV-2 challenge infection and a broad protection against Omicron BA.2, BA.5 and XBB.1.5, with reduced transmission. Finally, this promising LAV approach could be applicable to other emerging viruses.